Modernizing Surveillance of Antituberculosis Drug Resistance: From Special Surveys to Routine Testing by Zignol, Matteo et al.
VIEWPOINTS
Modernizing Surveillance of Antituberculosis Drug
Resistance: From Special Surveys to Routine Testing
Matteo Zignol, Wayne van Gemert, Dennis Falzon, Ernesto Jaramillo, Le ´opold Blanc, and Mario Raviglione
STOP TB Department, World Health Organization, Geneva, Switzerland
Resistance to antituberculosis drugs has been documented since the 1940s, when the ﬁrst medicines for tuberculosis were
introduced. Since the initiation in 1994 of a global project to monitor the development of drug-resistant tuberculosis, nearly
60% of all countries in the world have implemented surveillance activities. In the past 15 years, special surveys have been the
most common approach to investigate the frequency and patterns of drug-resistant tuberculosis. The major obstacle to the
expansion of routine surveillance activities has been the lack of laboratory capacity needed to detect resistance. We are now in
a new era for antituberculosis drug resistance surveillance due to the advent of new diagnostic tools and global commitment
towards universal access to care for all patients with tuberculosis, including those with drug-resistant disease. Routine
surveillance linked to patient care, which represents the best approach to monitor drug resistance, now has the possibility of
becoming a reality even in resource-limited countries.
Development of resistance to anti-
tuberculosis drugs was recognized shortly
after the initial introduction of chemo-
therapy for the treatment of tuberculosis.
The large majority of patients treated with
streptomycin in the ﬁrst Medical Research
Council randomized clinical trial in the
1940s acquired resistance to that drug [1].
The spread of drug-resistant strains was
soon recognized, and a survey of clinics in
England in the 1950s found that .5% of
patients with tuberculosis who had no
history of previous treatment had strains
resistant to at least 1 of the 3 major drugs
i nu s ea tt h a tt i m e[ 2 ] .I ti sk n o w nt o d a y
that at least 3 effective drugs used in
combination are needed to treat tubercu-
losis while preventing development of
drug resistance [3]. However, despite the
introduction of combination regimens
throughout the world many years ago, the
presence of drug resistance has been
progressively documented from an ever
wider geographical area [4]. Recent esti-
m a t e sb yt h eW o r l dH e a l t hO r g a n i z a t i o n
(WHO) suggest that nearly half million
cases of multidrug-resistant tuberculosis
(MDR-TB, deﬁned as tuberculosis caused
by strains of Mycobacterium tuberculosis
that are resistant to at least isoniazid and
rifampicin, the 2 most powerful ﬁrst-
line anti-TB drugs) emerged globally in
2008 [5].
Measuring the magnitude of drug re-
sistance, particularly that of MDR-TB and
extensively drug-resistant tuberculosis
(XDR-TB, deﬁned as MDR-TB with ad-
ditional resistance to a ﬂuoroquinolone
and at least 1 second-line injectable agent:
[amikacin, kanamycin, and/or capreo-
mycin]), in a patient population and
monitoring epidemiological trends is
critical to assess the performance of any
tuberculosis control program and design
effective standardized treatment regimens.
Drug resistance may be transmitted
(also called primary resistance) or ac-
quired. Primary resistance, which occurs
when the infecting strain is already re-
sistant to >1 antituberculosis drug at the
time of its ﬁrst encounter with the subject,
is an indicator of transmission in the
community. Acquired resistance, deﬁned
when the patient’s bacterial population
acquires resistance during treatment
consequent to exposure to inadequate
therapy, is an indication of poor patient
adherence to treatment, caregiver errors
in prescribing and administering drugs,
poor quality of drugs, and programmatic
problems, including drug stockouts [6, 7].
In this article, we describe the history
of drug resistance surveillance, detail the
direction into which it is moving in the
era of increased commitment towards
universal access to care and greater avail-
ability of diagnostics tools, and discuss the
continuing challenges it faces.
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A GLOBAL ANTI-
TUBERCULOSIS DRUG
RESISTANCE SURVEILLANCE
PROJECT
History of the Project
In 1994, the Global Project on Anti-
Tuberculosis Drug Resistance Surveil-
lance was initiated by the WHO and the
International Union against Tuberculo-
sis and Lung Diseases, aiming to mea-
sure the magnitude of drug-resistant
tuberculosis and to monitor trends [8].
At this time, a ﬁrst set of guidelines was
developed to assist national tuberculosis
control programs in conducting anti-
tuberculosis drug resistance surveys [9].
The guidelines were based on 3 main
principles that are still essential in to-
day’s drug resistance surveillance and
are described in detail elsewhere [10]:
(1) data should be representative of
the patients with tuberculosis in the
country/geographical setting under
study; (2) patients’ treatment histories
should be carefully obtained and available
medical records reviewed, to clearly de-
termine whether patients have or have
not previously received antituberculosis
drugs; and (3) laboratory methods for
antituberculosis drug susceptibility test-
ing should be selected from among those
recommended by WHO, and all labora-
tory processes should be quality-assured
in cooperation with a partner Suprana-
tional Reference Laboratory [8, 11–13].
Since 1994, ﬁve global reports on anti-
tuberculosis drug resistance surveillance
have been published [5, 14–17]. Drug
resistance data have been systematically
collected and analyzed from 114 coun-
tries worldwide (59% of all countries of
the world). Of these countries, only 42
can rely on continuous surveillance sys-
tems based on routine diagnostic drug
susceptibility testing of all patients. The
remaining 72 countries have relied on
special surveys of representative samples of
patients (Figure 1). Trends in drug re-
sistance are available for only 59 countries
or subnational settings in which .1d r u g -
resistance survey or surveillance procedure
was conducted during 1994–2009. Given
the limited availability of susceptibility
testing to second-line antituberculosis
drugs worldwide, a large number of
resource-limited countries do not have
yet the laboratory capacity to diagnose
XDR-TB, which has been identiﬁed in 68
countries thus far (Figure 2).
Methods of the Project
Since the beginning of the Global Project
on Anti-Tuberculosis Drug Resistance
Surveillance, 2 main mechanisms to
measure drug resistance have been used:
the organization of special surveys
(surveys are deﬁned as discrete studies
measuring drug resistance among a spe-
cially-designed sample of tuberculosis
cases representative of an entire pop-
ulation of TB cases) on selected samples
of patients, and the establishment
of a surveillance system based on
routine drug susceptibility testing of all
patients.
Over the past 15 years, special surveys
have been the most popular approach to
monitor drug resistance. Although sur-
veys face several limitations as described
below, in the absence of a feasible al-
ternative that could provide an equiva-
lent amount of information, they are still
used in resource-constrained settings with
limited laboratory capacity to routinely
monitor drug resistance [6].
Limitations of Surveys. Surveys face
a number of limitations. First, they may
be limited in their representativeness
and may possibly underestimate the true
magnitude of primary and acquired re-
sistance, particularly in settings where
Figure 1. Characteristics of available first-line antituberculosis drug resistance data, 1994–2010.
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munodeﬁciency virus (HIV) infection is
frequent or where patients with tuber-
culosis are commonly treated by private
health providers [18]. Second, surveys are
logistically complex and demanding,
taking considerable amounts of human
and ﬁnancial resources of the national
tuberculosis control program and refer-
ence laboratory during the planning,
implementation, and analysis phases of
a study [19]. Third, surveys often are not
able to monitor epidemiological trends,
because frequencies of drug resistance
among patient populations usually do
not change rapidly, and only small dif-
ferences would be expected between sur-
veys conducted a few years apart. The
smaller the difference in frequencies, the
larger the sample size would be needed to
detect a statistically signiﬁcant difference;
in most circumstances, this means that
excessively large sample sizes would be
needed. Fourth, surveys are not designed
to detect localized outbreaks, which could
go completely unrecognized even during
the course of a study if the outbreak site
was not among those selected for patient
enrollment. A different surveillance ap-
proach is needed to capture the hetero-
geneity of drug resistance at the local level
and avoid over- or underestimating the
magnitude of drug resistance by random
inclusion or exclusion of outbreaks. Fi-
nally, the precision of survey results is
usually suboptimal in countries with
relatively low frequencies of MDR-TB.
Sample sizes for surveys are calculated
to achieve a targeted precision for a pre-
deﬁned estimated proportion of MDR-
TB; the value of such a precision is
generally recommended to be no more
than 20% of the estimated proportion [6].
In settings with low frequencies of MDR-
TB, a high precision can not be reached
without capturing a sample that would be
s ol a r g ea st om a k et h es u r v e yu n f e a s i b l e .
Sentinel surveillance systems represent
ausefulinterimapproachforcountriesthat
intend to establish countrywide routine
drug susceptibility testing but that lack
necessary health care resources [6]. Under
sentinel surveillance, speciﬁc laboratory or
hospital sites are selected to routinely
perform drug susceptibility testing on all
notiﬁed tuberculosis cases. Ideally, sites are
selected that provide geographical vari-
ability and minimize bias. As laboratory
capacity is enhanced, more diagnostic sites
can progressively join the sentinel system
until routine surveillance in all sites is
achieved countrywide.
The only option to reduce bias and to
accurately measure the magnitude of
drug resistance and monitor its trends is
through the establishment of routine
surveillance, which implies systematic
ongoing collection, collation, and anal-
ysis of data for public health purposes, as
reiterated by the World Health Assembly
[20, 21].
MOVING TOWARDS ROUTINE
ANTITUBERCULOSIS DRUG
RESISTANCE SURVEILLANCE
In the past 15 years, surveys and surveil-
lance have been largely relying on culture
and drug susceptibility testing methods
based on solid media, which are associ-
ated with a very long turn-around times
for results (at least 3–4 months) and
enormous workload for laboratory per-
sonnel. We are now in a new era for tu-
berculosis and MDR-TB diagnosis
resulting from the advent of technological
advances that make it possible to detect
tuberculosis and rifampicin resistance
much more rapidly. For example, line
probe assays cut down the time of di-
agnosis of rifampicin resistance, which acts
as a proxy for MDR-TB in most settings,
to 2 days [22]. This technology can be
Figure 2. Countries that reported at least one case of extremely drug-resistant tuberculosis (XDR-TB) by end 2010.
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tum samples stored in ethanol, for which
it performs similarly to phenotypic drug
susceptibility testing to correctly identify
resistance to rifampicin. It requires less
laboratory infrastructure and workload and
allows for safer transportation of specimens
and simpliﬁed survey logistics [23, 24].
The time needed for diagnosis of tu-
berculosis and rifampicin resistance has
been cut down even further to 2 h by a
more recent diagnostic tool, Xpert MTB/
RIF [25]. This technology is almost
completely automated and very simple
to use, and it requires little training and
minimal biosafety measures. It has not
yet been tested on specimens preserved
in alcohol, which would further simplify
specimens’ transportation and logistics,
but—very importantly—this technique
has high sensitivity with smear-negative
specimens. With this tool, it will be
feasible to study frequencies of drug re-
sistance in patients with smear-negative
specimens, such as children, HIV-
positive patients, and others with pau-
cibacillary forms of tuberculosis. In the
past 15 years, patients with smear-negative
specimens have been excluded from sur-
veys to avoid excessive workload in the
laboratories and complex logistics, given
that the culture yield in this group is rel-
atively low, compared with that for smear-
positive cases [26]. More experience
should be gained to determine the best role
of this new technology in the diagnostic
algorithm for tuberculosis and MDR-TB as
well as in surveillance activities.
The WHO and the Global Laboratory
Initiative are committed to support the
expansion of new and rapid tuberculosis
diagnostic technologies in 27 countries
over the next 5 years through EXPAND-
TB, an extensive laboratory capacity–
building initiative [27]. This initiative will
greatly enhance the possibility for coun-
tries to diagnose MDR-TB and XDR-TB
using the most up-to-date technologies.
Although the aim is to improve diagnosis
and clinical care by expanding access to
drug susceptibility testing, a large amount
of population-level drug resistance data
will also be generated that, if properly
collected and analyzed, could be used by
national TB control programs for sur-
veillance purposes.
Access to routine molecular drug
susceptibility tests will be initially pri-
oritized among patients at higher risk of
carrying drug-resistant strains, such as
persons with history of tuberculosis
treatment [28]. For this reason, special
surveys or sentinel surveillance will still
have a role for several years to measure
the magnitude of drug resistance in pa-
tients not at high risk of drug resistance,
including those who have never pre-
viously been treated for tuberculosis.
The use of different surveillance ap-
proaches, such as Lot Quality Assurance
Sampling techniques that are already
used to investigate drug resistance
in HIV [29], or the development of
high-throughput single Nnucleotide
Ppolymorphism–basedsurveillancetech-
nologies could represent alternatives to
special surveys or sentinel surveillance to
improve our understanding of drug re-
sistance, particularly for persons who
have never previously been treated for
tuberculosis, until routine surveillance
becomes available everywhere.
In addition to greater availability of
diagnostic tests, we are in an era of en-
hanced commitment toward universal
access to treatment for all patients with
tuberculosis, including those who have
been previously treated. These patients
historically have received less attention by
country programs and the international
community, given that they usually have
more serious forms of disease that often
are more difﬁcult and expensive to di-
agnose and cure [30]. Previously treated
patients constitute a very heterogeneous
group composed of patients who experi-
ence relapse after receiving successful
treatment, those who return after default,
and those who start receiving a re-
treatment regimen after having experi-
enced previous treatment failure, as well
as other patients (ie, those who do not ﬁt
into one of the aforementioned cat-
egories), such as those who received
unknown or nonstandardized treatment
regimens [28]. Frequencies of MDR-TB
vary substantially between the different
categories of previously treated persons;
overall, the frequency is .60% in some
former Soviet Union settings. It is evident
that no single standardized re-treatment
regimen would be effective for all pre-
viously treated persons with tuberculosis,
and understanding the magnitude and
patterns of resistance in each of the cat-
egories mentioned above is crucial to
guide the choice of treatment [28, 31].
Routine surveillance of drug resistance
allows for proper treatment of all patients
with tuberculosis and is critical for accu-
rate planning, budgeting, and monitoring
of tuberculosis and MDR-TB control ac-
tivities. This is relevant for all countries,
including those with particularly limited
resources and where the management of
MDR-TB has to compete with other
pressing health needs in a context of in-
creasing ﬁnancial constraints. Even if the
majority of patients with tuberculosis
globally do not have drug-resistant in-
fection, the epidemiological situation may
change dramatically in a few years time if
drug-resistant cases are not adequately
managed [32]. The prospects of a suc-
cessful outcome of treatment for patients
with MDR-TB are much lower than for
those with drug-susceptible disease, with
only 60% of treatment success reached
globally, compared with 86% in the group
of new smear-positive patients [5, 33].
T h e s ef a c t sm a k et h es u r v e i l l a n c eo fd r u g
resistance today and in the coming years
even more pertinent than it was when the
Global Project on Anti-Tuberculosis Drug
Resistance Surveillance was launched.
CONTINUING CHALLENGES
IN DRUG RESISTANCE
SURVEILLANCE AND
POSSIBLE SOLUTIONS
Whether performing routine surveillance,
sentinel surveillance, or special surveys to
904 d CID 2011:52 (1 April) d Zignol et almonitor antituberculosis drug resistance,
3 major challenges are encountered: the
need to incorporate HIV testing, the need
to expand surveillance efforts to all health
care providers, and the need to assure
appropriate care to all those found with
drug-resistant disease.
Outbreaks of drug-resistant tubercu-
losis among people living with HIV in-
fection have been widely documented in
nosocomial and other congregate set-
tings. If not rapidly diagnosed and
treated, MDR-TB and XDR-TB can in-
deed lead to very high case-fatality rates
among persons with concurrent HIV
infection [34]. Unfortunately little in-
formation is available on the association
of HIV infection and drug-resistant tu-
berculosis at the population level [35,
36]. In recent years, national tuberculo-
sis control programs have experienced
great difﬁculties in incorporating HIV
testing in drug-resistant tuberculosis
surveillance activities, because this re-
quires strong collaboration and co-
ordination between tuberculosis and
HIV control programs. Knowing the
relationship between HIV and MDR-TB
epidemics at population level can help in
the identiﬁcation of high-risk groups
and in the planning of effective public
health control measures. Inclusion of
HIV testing should therefore be en-
couraged during antituberculosis drug
resistance surveillance activities.
In many regions of the world, patients
with tuberculosis symptoms seek care
from private health care providers before
approaching the services of the national
tuberculosiscontrolprogram [37]. In these
areas, private providers are often perceived
to deliver better services and treatment
options. In reality, this may not be the
case, because it is known that the majority
of patients seeking re-treatment in the
public sector had been unsuccessfully
treated in the ﬁrst instance by private
providers [38]. Drug-resistance surveys are
usually conducted only in the public sector
for logistic and organizational reasons.
Therefore, in countries with a large private
health care sector, these studies may not be
able to accurately capture the real magni-
tude of the problem. In such settings, it has
been suggested that drug-resistance surveys
i nt h ep u b l i cs e c t o rs h o u l db ec o m -
plemented by small surveys in the private
sector to determine the existence and di-
rection of any bias introduced by exclud-
ing private providers from surveys [18].
Additionally, public-private mix initiatives
can serve as platforms to gradually involve
private laboratories and practitioners in
surveillance activities.
In the early years of drug-resistance
surveillance, second-line drugs for the
treatment of MDR-TB generally were
completely unavailable in resource-
limited countries. Surveys were con-
ducted to estimate the magnitude of the
problem and helped to advocate for
more resources to diagnose and treat
patients with drug-resistant tuberculosis.
The disparity between the number
of patients with MDR-TB receiving
second-line treatment and those await-
ing diagnosis and/or treatment is still
enormous, with only 12% of those in
need estimated to have received treat-
ment in 2009 [33]. Globally the number
of centers capable of providing care to
patients with MDR-TB according to in-
ternational standards has increased, and
presently, most countries have at least
1 referral center for treatment with
second-line drugs [39]. In this changing
environment, implementation of surveys
and the scale-up of surveillance systems
for drug resistance should proceed in
parallel with the scale-up of MDR-TB
treatment services. This will ensure ap-
propriate treatment with second-line
antituberculosis drugs for all persons in
whom drug-resistance tuberculosis is
detected [6, 40].
CONCLUSIONS
Surveillance efforts have been monitoring
national and regional trends in drug-
resistant tuberculosis since the mid-1990s.
As a result of the recent commitment
towards provision of universal access to
care and the availability of new diagnostic
tools, we are now in a new era for anti-
tuberculosis drug resistance surveillance.
For the ﬁrst time in the history of tuber-
culosis control, technologies to rapidly
detect tuberculosis and rifampicin re-
sistance have become a reality, allowing
for surveillance activities with less de-
manding laboratory infrastructure and
capacity. Although neither rapid diagnosis
nor treatment for MDR-TB is currently
widely available, there is an unprecedented
level of political commitment and re-
source mobilization to accelerate access in
the coming few years, changing the way in
which drug resistance is monitored. Rou-
tine surveillance linked to patient care will
gradually replace special surveys that, until
now, have been the main approach to
monitor drug resistance in resource-
limited countries. Because resource-
limited programs are making efforts to
establish routine drug susceptibility testing
of all patients with histories of previous
treatment, a new opportunity has been
made available to obtain surveillance data
for use in strengthening TB control pro-
gram planning and performance.
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